Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O'Neill GN; BG-12 Phase IIb Study Investigators. Kappos L, et al. Among authors: dawson kt. Lancet. 2008 Oct 25;372(9648):1463-72. doi: 10.1016/S0140-6736(08)61619-0. Lancet. 2008. PMID: 18970976 Clinical Trial.
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT; DEFINE Study Investigators. Gold R, et al. Among authors: dawson kt. N Engl J Med. 2012 Sep 20;367(12):1098-107. doi: 10.1056/NEJMoa1114287. N Engl J Med. 2012. PMID: 22992073 Free article. Clinical Trial.
Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study.
Kita M, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Sarda SP, Agarwal S, Kong J, Zhang A, Viglietta V, Sheikh SI, Seidman E, Dawson KT. Kita M, et al. Among authors: dawson kt. Mult Scler. 2014 Feb;20(2):253-7. doi: 10.1177/1352458513507818. Epub 2013 Oct 22. Mult Scler. 2014. PMID: 24150778 Clinical Trial.
Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study.
Arnold DL, Gold R, Kappos L, Bar-Or A, Giovannoni G, Selmaj K, Yang M, Zhang R, Stephan M, Sheikh SI, Dawson KT. Arnold DL, et al. Among authors: dawson kt. J Neurol. 2014 Dec;261(12):2429-37. doi: 10.1007/s00415-014-7504-7. Epub 2014 Oct 1. J Neurol. 2014. PMID: 25270680 Free PMC article. Clinical Trial.
Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97.
Havrdova E, Hutchinson M, Kurukulasuriya NC, Raghupathi K, Sweetser MT, Dawson KT, Gold R. Havrdova E, et al. Among authors: dawson kt. Expert Opin Pharmacother. 2013 Oct;14(15):2145-56. doi: 10.1517/14656566.2013.826190. Epub 2013 Aug 24. Expert Opin Pharmacother. 2013. PMID: 23971970
Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials.
Viglietta V, Miller D, Bar-Or A, Phillips JT, Arnold DL, Selmaj K, Kita M, Hutchinson M, Yang M, Zhang R, Dawson KT, Sheikh SI, Fox RJ, Gold R. Viglietta V, et al. Among authors: dawson kt. Ann Clin Transl Neurol. 2015 Feb;2(2):103-18. doi: 10.1002/acn3.148. Epub 2014 Dec 4. Ann Clin Transl Neurol. 2015. PMID: 25750916 Free PMC article.
20 results